October 30, 2019

Despite anatomy being the first topic to challenge the student in medical school for over 150 years, attention to variation of drug targets across tissues in the human body has remained scant even to the present day. GeneCentrix has pioneered the incorporation of trans...

October 30, 2019

It seems like an obvious concept: Let's say you are developing a drug that works by inhibiting, say, phosphodiesterase-4 (PDE-4) to treat depression (fictional). You have collected immense molecular, cellular, animal and clinical data supporting and validating PDE-4 as...

February 28, 2019

Just when you thought you were out, they pull you back in. We in the business obsess over the “valley of death” and the drug development milestones around it at early and preclinical stages of drug development, but danger also lies beyond our horizon.

Normally, when we...

February 28, 2019

Context counts.  If you are running towards the scene of a crime, you are doing something and you ARE something VERY different than if you are running away from the scene of a crime.  It's exactly the same thing: running, but the context makes the phenotype completely...

October 18, 2018

Thinking about battling cancer without understanding its tissue of origin would be like hiring someone without knowing about their previous employment.  This vintage book review organizes some great, old thoughts on tissue specificity for anti-cancer drug developm...

October 18, 2018

Clinical holds are lost battles in the war against drug attrition.  The process of drug development critically revolves around the FDA’s Investigational New Drug (IND) application, which is the document required to start testing the drug in humans.  Any safety, efficac...

October 18, 2018

Some autoimmune diseases, like lupus, affect multiple tissues, but some, like inflammatory bowel disease, affect only specific types.  A new study reveals that HDAC7 controls tissue-specific autoimmunity in othertissues via its action in the thymus, a mechanism which y...

September 5, 2018

Everyone knows that off-targets are the bane of a drug developers existence, but surprisingly little has been done to address the problem. Nature’s paper from the time machine, “Reducing safety-related drug attrition: the use of in vitro pharmacological profiling,” des...

Please reload

THE GENE

EXPRESS

Recent News

Sick factor

June 2, 2020

Fast and spurious

June 2, 2020

Screen stars

June 2, 2020

1/4
Please reload

Tags